Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01930162 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT01930162 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 9 participants.
The verdict
NCT01930162, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study was designed to evaluate the safety and tolerability of HSC835 for clinical use as measured by the absence of graft failure at day 42 in excess of that currently observed with double umbilical cord blood (UCB) transplantation (DUCBT) with non-myeloablative (NMA) conditioning.
Interventions
- DRUG HSC835
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-10-07 |
| Est. Completion | 2016-08-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01930162
The ClinicalTrials.gov registry entry for NCT01930162 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HSC835 is the first listed.
NCT01930162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01930162 about?
NCT01930162 is a clinical study titled "Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant". This study was designed to evaluate the safety and tolerability of HSC835 for clinical use as measured by the absence of graft failure at day 42 in excess of that currently observed with double umbilical cord blood (UCB) transplantation (DUCBT) with non-myeloablative (NMA) conditioning.
What is the current status of trial NCT01930162?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2014-10-07. Estimated completion is 2016-08-29.
What interventions are being tested in trial NCT01930162?
The interventions under investigation include: HSC835 (DRUG).
Who is sponsoring clinical trial NCT01930162?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.